Immuron anticipates receiving FDA approval for its IND submission.
4 reports, 3 independent
Updated Aug 28
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Immuron anticipates receiving FDA approval for its IND submission.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Immuron seeks FDA IND approval and receives DoD funding for research with Walter Reed.1 source
Immuron secured FDA IND approval and established three Australian clinical sites.1 source
Immuron anticipates FDA approval for its IND submission.1 source
Keep exploring
The entities involved
Related events
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- Takeda announced FDA approval of its drug MIMRYLO, a decision supported by VERIFY results.
- BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
- The FDA has issued a Major Amendment regarding AxoGen's submission on August 25, 2025.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- manilatimes.net
- GlobeNewswireImmuron partners with InvestorHub MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct
- GlobeNewswireImmuron - FY25 global sales exceed projection, up 49% on prior year Sales Highlights (unaudited): MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an